EUVIMEDEUVIMED entdecken
Kohortenstudie

Discontinuation of belimumab in systemic lupus erythematosus patients who achieved disease stability: a retrospective cohort study

Yanxia Ren, Tingting Yan, Chao Wang

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-025-07571-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Yanxia Ren und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents, Withholding Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To investigate the changes in various indicators of systemic lupus erythematosus (SLE) patients who discontinue belimumab after achieving disease stability, assess the potential impacts and risks of discontinuing belimumab, and provide scientific evidence and references for clinical decision-making. METHODS: Pertinent data were retrospectively collected from SLE patients at the Second Affiliated Hospital of Jiaxing University who either discontinued or continued belimumab treatment after achieving disease stability. The study compared changes in disease activity, glucocorticoid usage, immunological markers, and other relevant indicators between the two groups after 6 months of follow-up. RESULTS: After 6 months of follow-up, patients in the experimental group exhibited increased Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2000) scores, enhanced activity of immunological markers, a greater proportion of patients requiring increased glucocorticoid doses, and experienced new-onset systemic involvement. Notably, only 20% of these patients achieved low disease activity state (LLDAS). In contrast, patients in the control group experienced decreased SLEDAI-2000 scores, improved immunological markers, and a greater proportion requiring a reduction in glucocorticoid dosage, with 76.67% achieving LLDAS. The differences between the two groups were statistically significant (P < 0.05). No statistically significant difference was observed between the two groups concerning hospital readmissions due to disease activity, new organ damage, or the incidence of adverse events. CONCLUSIONS: Discontinuing belimumab in patients with stable SLE may lead to higher glucocorticoid requirements, enhanced activity of immunological markers, increased disease activity, and new-onset systemic involvement. Research in this area is necessary and can provide certain reference and guidance for clinical decision-making. Key Points • The subsequent conditions of SLE patients who discontinue belimumab after achieving disease stability warrant attention. • Discontinuing belimumab may lead to higher glucocorticoid requirements, enhanced activity of immunological markers, increased disease activity, and new-onset systemic involvement. • These findings provide crucial decision-making references and may help reduce unnecessary discontinuations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsWithholding TreatmentHumansRetrospective StudiesFemaleMaleAdultMiddle AgedSeverity of Illness IndexGlucocorticoidsTreatment Outcome

Stichwörter der Autor:innen

Belimumab discontinuationDisease activityGlucocorticoidImmunological markersSystemic lupus erythematosus

Substanzen

belimumabAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsGlucocorticoids

Autor:innen und Institutionen

  • Department of Internal Medicine, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Department of Rheumatology and Immunology, The Second Affiliated Hospital of Jiaxing University, Jiaxin, Zhejiang, China.
  • Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. cwzu@zju.edu.cn.
  • National Engineering Research Center of Innovation and Application of Minimally Invasive Instruments, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. cwzu@zju.edu.cn.

Förderung

  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Ren, Y., Yan, T., & Wang, C. (2025). Discontinuation of belimumab in systemic lupus erythematosus patients who achieved disease stability: a retrospective cohort study. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07571-0

Vancouver

Ren Y, Yan T, Wang C. Discontinuation of belimumab in systemic lupus erythematosus patients who achieved disease stability: a retrospective cohort study. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07571-0

BibTeX
@article{Ren2025,
  author = {Ren, Yanxia and Yan, Tingting and Wang, Chao},
  title = {Discontinuation of belimumab in systemic lupus erythematosus patients who achieved disease stability: a retrospective cohort study},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-025-07571-0}
}
Kostenlos starten →